tixulda 50 mg/500 mg modificētās darbības tabletes
adamed pharma s.a., poland - sitagliptinum, metformini hydrochloridum - modificētās darbības tablete - 50 mg/500 mg
tixulda 50 mg/1000 mg modificētās darbības tabletes
adamed pharma s.a., poland - sitagliptinum, metformini hydrochloridum - modificētās darbības tablete - 50 mg/1000 mg
tixulda 100 mg/1000 mg modificētās darbības tabletes
adamed pharma s.a., poland - sitagliptinum, metformini hydrochloridum - modificētās darbības tablete - 100 mg/1000 mg
jansitin duo 50 mg/850 mg apvalkotās tabletes
g.l. pharma gmbh, austria - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg
jansitin duo 50 mg/1000 mg apvalkotās tabletes
g.l. pharma gmbh, austria - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg
juzimette 50 mg/1000 mg apvalkotās tabletes
gedeon richter plc., hungary - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg
juzimette 50 mg/850 mg apvalkotās tabletes
gedeon richter plc., hungary - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg
jamesi 50 mg/850 mg apvalkotās tabletes
zentiva, k.s., czech republic - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg
jamesi 50 mg/1000 mg apvalkotās tabletes
zentiva, k.s., czech republic - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg
jalra
novartis europharm limited - vildagliptin - cukura diabēts, 2. tips - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 un 5. 1 pieejamo datu par dažādām kombinācijām).